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Abstract: There is increasing evidence of the linkage
between type 2 diabetes mellitus (T2DM) and gut
microbiota. Based on our previous studies, we investigated the hypoglycemic mechanisms of yam gruel to
provide a scientiﬁc basis for its popularization and
application. Wistar rats were randomly divided into
control and T2DM model groups. Rats in the model group
were stimulated by a high-sugar/high-fat diet combined
with an intraperitoneal injection of streptozotocin to
induce T2DM. The T2DM rats were further subdivided
randomly into three groups: (1) DM, (2) DM + yam gruel,
and (3) DM + metformin. After 4 weeks of intervention,
the changes in gut microbiota, short-chain fatty acids
(SCFAs) (acetic acid, propionic acid, and butyric acid),
the expression of G protein-coupled receptor 43 (GPR43),
glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and
fasted blood glucose (FBG) levels were observed. Yam
gruel intervention elevated the abundance of probiotic
bacteria and increased the expression of SCFAs, GPR43
receptor, GLP-1, and PYY. It also reduced FBG levels. We
conclude that yam gruel can lower FBG by promoting the
growth of probiotic bacteria, increasing the content of
SCFAs, and enhancing the expression of GPR43 receptor to
increase the content of GLP-1 and PYY in serum.

Abbreviations
T2DM
type 2 diabetes mellitus
STZ
streptozotocin
SCFAs short-chain fatty acids
GPR43 G protein-coupled receptor 43
GLP-1
glucagon-like peptide-1
PYY
peptide YY
FBG
fasted blood glucose
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1 Introduction
Diabetes mellitus is one of the most critical chronic
noncommunicable diseases, threatening human health
around the world. According to the statistics of the
International Diabetes Federation, the number of diabetes patients worldwide reached 463 million in 2019
and is expected to rise to 578 million by 2030.
Approximately 116 million people are living with
diabetes mellitus in China, among whom type 2 diabetes
mellitus (T2DM) accounts for more than 90% [1,2]. The
morbidity of T2DM remains high, with numerous and
severe complications that place heavy economic and
care burdens on families and society [3–5].
With advances in research, the gut microbiota has
increasingly become a new target for the prevention and
treatment of T2DM [6]. In T2DM patients, the abundance
of probiotics such as Biﬁdobacterium in the intestinal
tract has been shown to decrease while the level of
opportunistic pathogens such as Bacteroides increased
signiﬁcantly [7,8]. Furthermore, recent studies have
reported that the abundance of probiotic bacteria can
substantially inﬂuence the level of short-chain fatty
acids (SCFAs), such as acetic acid, propionic acid, and
butyric acid. Streptococcus [9], Oscillospira [10], and
Phascolarctobacterium [11] are well-known SCFAproducing bacteria, the decrease of which could lead to
a reduction in SCFAs. SCFAs are a regulatory signal
This work is licensed under the Creative Commons Attribution 4.0

764 

Xinjun Lin et al.

of metabolism that can directly activate G proteincoupled receptor 43 (GPR43), promote the secretion of
glucagon-like peptide-1 (GLP-1) and peptide YY (PYY),
improve fasting hyperglycemia, and delay the development of diabetes [12,13].
It is well accepted that a sensible diet can be a
primary factor of gut microbiota structure as well as an
essential intervention for diabetes. Dietary nursing in
traditional Chinese medicine is a special nutritional
intervention that can be used as both food and medicine.
Yam gruel is a classic food therapy documented in the
Records of Traditional Chinese and Western Medicine in
Combination written by Zhang [14]. A previous study by
our group showed that yam gruel can facilitate the
growth of Biﬁdobacterium and help lower blood glucose
levels [15,16]. However, the speciﬁc hypoglycemic
mechanism of yam gruel is unclear.
The current study aimed to determine the eﬀects of
yam gruel on the gut microbiota and SCFAs and to
evaluate other vital indicators, including the GPR43
receptor, GLP-1, PYY, and fasted blood glucose (FBG).
Ultimately, we believe that this work provides novel
insight into the hypoglycemic mechanism of yam gruel
and insight into T2DM prevention, providing a scientiﬁc
basis for the popularization and application of yam gruel.

2 Materials and methods
2.1 Preparation of yam gruel
Raw Dioscorea polystachya, common name Chinese yam
or “Huai Qing Fu” yam, was ordered and conﬁrmed for
its originality by a pharmacologist. The desired
Dioscorea polystachya was cylindrical in shape of at
least 2 cm in diameter with much mucus. The raw
Dioscorea polystachya used in the study was purchased
and immediately stored in the refrigerator. Following the
classic recipe described in the Records of Traditional
Chinese and Western Medicine in Combination [14], and
the dosage used in our previous study [15], yam gruel
was prepared every morning. The speciﬁc method was as
follows: raw Dioscorea polystachya was peeled and
sliced (125 g), mixed with 50 mL of water in a cooker
and beaten into a paste. Cold water (250 mL) was added,
and the yams were boiled over medium heat for 30 s. The
mixture was boiled again for 30 s over low heat, and
then the heat was turned oﬀ for 30 s. The procedure was
repeated three times. During the processing, continual
stirring is important to avoid yam sticking to the bottom of

the cooker. Finally, the yam gruel was boiled in
approximately 250 mL aliquots, which were about 0.5 g
of yam per 1 mL, and then cooled to 37°C prior to use.

2.2 Animals and diet
Six-week-old male Wistar rats (150 ± 10 g) were
purchased from Shanghai Slack Laboratory Animal Co.,
Ltd (Shanghai, China). All rats were housed in cages at a
temperature between 25 ± 2°C and 55 + 5% humidity,
maintaining a 12-h light/dark cycle (light on 08:00–
20:00). The rats were given free access to food and
water. After 1 week of adaptive feeding, 38 rats were
randomly divided into a normal control (NC) group (n = 8)
fed with a standardized diet, and a model group (n = 30)
fed with a high-sugar/high-fat diet. The standardized diet
was provided by the Animal Experiment Centre of Fujian
University of Traditional Chinese Medicine, while the
high-sugar/high-fat diet (10.0% lard, 15.0% sucrose, 4%
cholesterol, 10% yolk powder, 0.3% cholate, and 60.7%
standard diet) was provided by Minhou Wushi
Experimental Animal Trading Co., Ltd (Fuzhou, China).
After 6 weeks, all rats were fasted for 12 h. The rats in the
model group were intraperitoneally injected with 1%
streptozotocin (STZ) solution twice at a dose of 25 mg/kg
(interval 2 days) while the NC group received an intraperitoneal injection of citric acid buﬀer at the same dose. After
1 week of observation, blood samples were collected from
the tail vein once a day for two consecutive days and FBG ≥
11.1 mmol/L was determined as a standard for T2DM rat [17].
T2DM rats were randomly divided into three subgroups: (1)
DM (normal saline, n = 8), (2) DM + yam gruel (yam gruel,
n = 7), and (3) DM + metformin (metformin, as a positive
control, 100 mg/kg/day, n = 8). All interventions were
delivered in a liquid state via a gavage needle, and the dose
of gavage was set to be 15 mL/kg/day. Rats were fed with a
standardized diet throughout the intervention. After 4
weeks of intervention, the rats were anaesthetized with
pentobarbital (35 mg/kg, i.p.) and killed by cervical
dislocation. Subsequently, blood from the abdominal aorta
and stool from the colon were collected. Colon tissues were
obtained rapidly, washed with ice cold phosphate-buﬀered
saline, and then stored at −80°C.
Ethical approval: The research related to animal use has
been complied with all the relevant national regulations
and institutional policies for the care and use of animals
and has been approved by the Animal Experiment
Committee of the Fujian University of Traditional
Chinese Medicine (2019-015).

The hypoglycemic eﬀects of yam gruel

2.3 Measurement of gut microbiota
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Next, 2 mL of the supernatant was diluted with 0.5 mL of
50% sulfuric acid and dissolved for 30 s. After that, 2 mL
of ethyl ether was added, oscillated for 2 min, centrifuged for 10 min at 7,000 rpm, and 1 mL of the ethyl
ether layer was used for gas chromatography-mass
spectrometry analysis. The standard substances of acetic
acid, propionic acid, and butyric acid were dissolved in
ether as a standard solution. Helium was used as the
carrier gas and the ﬂow rate was set to be 1.18 mL/min.
A temperature program was carried out as follows: start
at 80°C for 1 min, at 20°C/min up to 180°C, then at
40°C/min up to 240°C, and maintained for 5 min. The
inlet port temperature was 230°C, and the transmission
line was 240°C, running for 12 min. The scan range was
20–200 m/z with the mode of SCAN and SIM. Monitored
ions included acetate acid 43, 45, 60 m/z; propionate
acid 29, 45, 73, 74 m/z; and butyrate acid 60, 73, 88 m/z.
Ion source temperature was 200°C, and EI source
bombardment energy was 70 eV.

Gut microbiota was detected by 16S rRNA gene sequencing technology. Microbial DNA was extracted from each
sample using the QIAamp®DNA Stool Mini Kit (Hilden,
Germany) according to the manufacturer’s instructions.
DNA concentrations were determined using a Qubit
quantiﬁcation system (Thermo Scientiﬁc, Wilmington,
DE, USA). The microbial V3-V4 hypervariable region of
the 16S rRNA gene was ampliﬁed from genomic DNA
using the primers 341 F (CCTACGGGNGGCWGCAG) and
805 R (GACTACHVGGGTATCTAATCC). Ampliﬁcation was
performed in a reaction mixture consisting of 1X KAPA
HiFi Hot start Ready Mix, 0.1 µM primer 341 F, 0.1 µM
primer 805 R, and 12.5 ng template DNA, giving a total
volume of 50 µL per sample. Reactions were run in a
T100PCR thermocycler (BIO-RAD) according to the
following cycling program: 3 min of denaturation at
94°C, followed by 18 cycles of 30 s at 94°C (denaturation), 30 s at 55°C (annealing), and 30 s at 72°C
(elongation), with a ﬁnal extension at 72°C for 5 min.
Subsequently, the ampliﬁed products were checked by
2% agarose gel electrophoresis and ethidium bromide
staining. Amplicons were quantiﬁed using the Qubit
quantiﬁcation system and puriﬁed with Agencourt
AMPure XP Beads (Beckman Coulter Genomics, MA,
USA). The concentration of the pooled libraries were
determined using the Qubit quantiﬁcation system.
Amplicon sequencing was performed on a HiSeq 2500
PE 250 (Illumina, Inc, USA).
Clean reads were ﬁltered to get more accurate and
reliable reads; this was achieved by splicing based on
the overlap to get clean tags. The clean tag sequences
obtained from each sample were combined, and the
Usearch 10.0 standard UPARSE-OUT algorithm method
was used for the cluster analysis of operational
taxonomic units (OTUs) with a similarity of 97%. The
similarity between the OTU sequence and the 16S
sequence of known bacteria was compared to obtain
the species classiﬁcation information of OTU. Finally,
the species and abundance of the microbiota in the
samples were analyzed.

Total RNA was extracted from the frozen colon tissues
using Trizol reagent (Wuhan Servicebio Technology Co.,
Ltd, Wuhan, China) and transcribed into cDNA using a
cDNA synthesis kit (Thermo Fisher Scientiﬁc, New York,
USA). The following primers were used: GPR43 F (5′CGGACTTGCTGTTGTTGCT-3′) and GPR43 R (5′-TGCTCG
GTTGAGTTCAGGTA-3′), β-actin F (5′-GTACCGCTGGGACC
CTACAC-3′) and β-actin R (5′-AGCGTGGTGATGGCGTA
GAA-3′). The ampliﬁcation and detection of quantitative
PCR products were performed with a 7500 real-time
ﬂuorescence quantitative PCR system (Corbett Company,
Australia). The PCR was performed according to the
following conditions: initial denaturation at 94°C for
31 s, denaturation at 94°C for 5 s, annealing at 60°C for
30 s, and extension at 60°C for 30 s, which was repeated
for 40 cycles. The method of calculating GPR43 mRNA
levels was the comparative 2−ΔΔCt.

2.4 Measurement of SCFAs

2.6 Western blot analysis

SCFAs were detected by gas chromatography–mass
spectrometry. One gram of stool and 10 mL of distilled
water were put into a centrifuge tube. After being fully
oscillated, a centrifuge was run at 12,000 rpm for 5 min.

Total protein was extracted from the frozen colon tissues
by homogenization and quantiﬁed using the BCA protein
quantitation assay (Fuzhou Watson Biotechnology Co.,
Ltd, Fuzhou, China). Equal amounts of protein (40 μg)

2.5 RNA extraction and reverse
transcription quantitative PCR
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and appropriate marker (3 μL) were loaded onto 10%
sodium dodecyl sulfate-polyacrylamide gels, separated
by electrophoresis, and then transferred to PVDF
membranes. Subsequently, the membranes were incubated in 5% skim milk on a shaker at room temperature
for 1 h, and then rinsed with Tris-buﬀered saline Tween
(TBST) for three 5 min cycles. Membranes were then
incubated overnight at 4°C with the primary antibody
GPR43 (1:300; Proteintech, Chicago, USA). Membranes
were washed with TBST as described above and
incubated with the secondary antibody (Wuhan
Servicebio Technology Co., Ltd, Wuhan, China) on a
shaker at room temperature for 1 h, and then rinsed with
TBST as before. Subsequently, equal doses of ECL
reagent A and reagent B (Wuhan Servicebio
Technology Co., Ltd, Wuhan, China) were mixed in a
dark room. The PVDF membrane was put into the
development box, and 200 µL of developer solution and
reactor were added for 2 min. The membrane was placed
in a dark box for exposure. After the exposure was
completed, the exposure bands were photographed with
an automatic gel imaging system (Liuyi Instrument
Factory, Beijing, China). The gray value of the protein
bands was measured, and the relative expression of the
GPR43 receptor was calculated.

2.7 Measurement of GLP-1, PYY, and FBG
levels in serum
Blood samples were centrifuged at 3,000 rpm for 15 min
at 4°C, and the serum was collected and stored at −80°C
for later analysis. Serum levels of GLP-1 and PYY were
determined using an ELISA kit (Nanjing Jiancheng
Bioengineering Institute, Jiangsu, China), and blood
glucose concentration was measured by the glucose
oxidase method with a reagent kit (Nanjing Jiancheng
Bioengineering Institute, Jiangsu, China).

hoc test or Dunnett’s T3 post hoc test. Statistical
signiﬁcance was deﬁned as P < 0.05.

3 Results
3.1 Changes in body weight across
intervention groups
During the intervention, the average body weight of the
DM group was signiﬁcantly lower than that of the NC
group (P < 0.01). Additionally, after the administration
of yam gruel or metformin, body weight was signiﬁcantly
increased at 4 weeks compared to the DM group (P <
0.05, Figure 1).

3.2 Eﬀects of yam gruel on FBG
To study the eﬀect of yam gruel on the blood glucose
levels of T2DM rats, FBG was measured before the
intervention and at the end of a 4-week intervention. As
shown in Figure 2, at the beginning of the intervention,
there was no hyperglycemia in the NC group, while the
high-sugar/high-fat diet combined with an intraperitoneal injection of STZ-treated rats showed diﬀerent
degrees of hyperglycemia. After 4 weeks of the intervention, compared with the NC group, FBG was
signiﬁcantly increased in the DM group (P < 0.01).

2.8 Statistical analysis
SPSS 20.0 software was used for data analysis, and data
were expressed as mean ± standard deviation (SD). Body
weight was analyzed using a repeated-measures analysis
of variance, and FBG levels were analyzed by Student’s
t-test. All other data or group diﬀerences were analyzed
using one-way analysis of variance followed by LSD post

Figure 1: Changes in body weight during the 4-week intervention in
diﬀerent groups. Values are expressed as mean ± SD, n = 7 or 8.
*
P < 0.05 and **P < 0.01 vs NC group, #P < 0.05 and ##P < 0.01 vs DM
group.

The hypoglycemic eﬀects of yam gruel
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Figure 2: Eﬀects of yam gruel on FBG. Values are expressed as mean ± SD, n = 7 or 8. *P < 0.05 and **P < 0.01 vs NC group, #P < 0.05 and
##
P < 0.01 vs DM group, ΔP < 0.05 and ΔΔP < 0.01 vs 0 week.

Following the administration of yam gruel or metformin,
the FBG levels were signiﬁcantly lowered compared with
the DM group (P < 0.01), but there were no signiﬁcant
diﬀerences between the two groups. In addition,
intragroup comparison showed that the FBG levels of
rats in the DM + yam gruel group and the DM +
metformin group were signiﬁcantly lower than those
before intervention (P < 0.05).

3.3 Eﬀects of yam gruel on the
characteristics of gut microbiota
The characterization of gut microbiota was performed
using OTU numbers, the Shannon diversity index, and
the Chao1 index (Figure 3). Compared with that of the NC
group, the numbers of OTU, Chao1 index, and Shannon
index were signiﬁcantly decreased in the DM group
(P < 0.01). Additionally, supplementation of yam gruel
could further reduce the above three indicators. However, only the numbers of OTUs were reduced signiﬁcantly in the DM + metformin group compared with the
DM group (P < 0.01).

3.4 Eﬀects of yam gruel on the relative
abundances of diﬀerent bacteria in the
gut microbiota
At the phylum level (Figure 4a), the majority of the
species in the gut microbiota were Firmicutes, Bacteroidetes, and Proteobacteria. There were some diﬀerences
between the groups. Compared with the NC group, the
DM group had a signiﬁcantly decreased abundance of

Firmicutes and an increased abundance of Bacteroidetes
(P < 0.05). However, the intervention of yam gruel or
metformin increased the abundance of Firmicutes and
decreased the abundance of Bacteroidetes in T2DM rats
(P < 0.05). At the genus level (Figure 4b), there was a
reduced abundance of SCFA-producing bacteria (such as
Streptococcus, Oscillospira, and Phascolarctobacterium)
in the DM group compared to the NC group (P < 0.05).
Furthermore, rats in the DM group had a greater
abundance of Bacteroides (P < 0.05). Yam gruel or
metformin supplementation signiﬁcantly elevated the
levels of Streptococcus, Oscillospira, and Phascolarctobacterium and decreased the Bacteroides level compared
with the DM group (P < 0.05).

3.5 Eﬀects of yam gruel on SCFAs
SCFAs (including acetic acid, propionic acid, and butyric
acid) were measured as shown in Figure 5. Comparing
the concentration of acetic acid, propionic acid, and
butyric acid between the NC group and the DM group, all
had a lower level in the DM group (P < 0.05).
Additionally, there was an increased concentration of
acetic acid, propionic acid, and butyric acid after 4
weeks of supplementation with yam gruel or metformin
in T2DM rats.

3.6 Eﬀects of yam gruel on the GPR43
receptor expression in colon tissues
As shown in Figure 6, compared with the NC group, both
gene and protein levels of the GPR43 receptor were
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3.7 Eﬀects of yam gruel on the levels of
GLP-1 and PYY in serum
GLP-1 and PYY were measured as shown in Figure 7.
Comparing the levels of GLP-1 and PYY in the NC group
and the DM group, both were lowered in the DM group
(P < 0.05). There was also an increased level of GLP-1
and PYY after the supplementation of yam gruel in T2DM
rats. On the contrary, only the PYY levels displayed
signiﬁcant diﬀerences between the DM group and the
DM + metformin group.

4 Discussion

Figure 3: Eﬀects of yam gruel on the characteristics of gut
microbiota. (a) OTU numbers of each group. (b) Chao1 index of each
group. (c) Shannon diversity index of each group. Values are
expressed as mean ± SD, n = 7 or 8. *P < 0.05 and **P < 0.01 vs NC
group, #P < 0.05 and ##P < 0.01 vs DM group.

signiﬁcantly reduced in the DM group (P < 0.01).
Additionally, the expression of the GPR43 receptor was
signiﬁcantly enhanced in the DM + yam gruel group and
in the DM + metformin group (P < 0.01).

In this study, we investigated the antidiabetic eﬀect of
yam gruel in T2DM rats and analyzed the potential
hypoglycemic mechanism. The results demonstrated that
yam gruel could signiﬁcantly reduce the diversity of gut
microbiota, promote the growth of probiotic bacteria
(especially SCFA-producing bacteria) in T2DM rats, and
enhance the expression of GPR43 receptor in colon
tissues to increase the content of GLP-1 and PYY in
serum and play a hypoglycemic role. In addition,
metformin (the preferred oral drug for lowering hyperglycemia [18]) was selected as the positive control drug
in the present study. We found that the levels of FBG
were signiﬁcantly lower in T2DM rats treated with yam
gruel or metformin and that there were no signiﬁcant
diﬀerences between the two groups, which suggests that
the hypoglycemic eﬀect of yam gruel was similar to
metformin. In summary, dietary supplementation of yam
gruel might be useful in improving fasting hyperglycemia, which provides a novel therapeutic option for the
prevention or treatment of T2DM.
T2DM is a chronic metabolic disease characterized
by fasting hyperglycemia, which is aﬀected by multiple
factors such as genetic, gut microbiota, lifestyle, and
dietary patterns [19]. With advancements in research,
the relationship between gut microbiota and T2DM has
been further clariﬁed. Zhao et al. [8] reported that there
was a moderate-intensity imbalance of gut microbiota in
T2DM patients, which was mainly manifested as the
decrease in probiotic bacteria and the increase in
pathogenic bacteria. Additionally, SCFAs as the primary
metabolite of intestinal probiotic have been proposed to
be closely related to the level of FBG. For example,
increasing the content of SCFAs is conducive to improve
insulin resistance and stable maintenance of blood

The hypoglycemic eﬀects of yam gruel
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Figure 4: Eﬀects of yam gruel on the relative abundances of gut microbiota at the (a) phylum and (b) genus taxonomic level in each group.
Species that could not be annotated at the genus level were classiﬁed into the “unclassiﬁed” category.
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Figure 6: Eﬀects of yam gruel on the GPR43 receptor expression in
colon tissues. (a) mRNA levels of GPR43 of each group. (b) Protein
levels of GPR43 of each group. Values are expressed as mean ± SD.
*
P < 0.05 and **P < 0.01 vs NC group, #P < 0.05 and ##P < 0.01 vs DM
group.
Figure 5: Eﬀects of yam gruel on SCFAs. (a) Acetic acid level of each
group. (b) Propionic acid level of each group. (c) Butyric acid level
of each group. Values are expressed as mean ± SD, n = 7 or 8. *P <
0.05 and **P < 0.01 vs NC group, #P < 0.05 and ##P < 0.01 vs DM
group.

glucose [11]. According to a clinical trial in 2017, T2DM
patients treated with multiple strains of probiotics for
12 weeks demonstrated signiﬁcantly improved insulin resistance [20]. Zhao et al. [12] reported that the enhanced
abundance of Phascolarctobacterium and other probiotic
bacteria could reduce the release of inﬂammatory factors
and suppress hepatic gluconeogenesis, resulting in a
lower level of FBG. Our data showed that the

intervention of yam gruel could promote the growth of
intestinal probiotics such as Streptococcus, Oscillospira,
and Phascolarctobacterium, increase the content of
SCFAs, and signiﬁcantly reduce the level of FBG in
T2DM rats. We speculated that this might be related to the
composition of yam gruel. Yam gruel consists only of raw
Chinese yam, which is regarded as a natural, hypoglycemic crop that has been widely used in the prevention
and treatment of diabetes in ancient China [21].
On the other hand, modern medicine postulates that
Chinese yam is rich in resistant starch, dietary ﬁber,
polysaccharides, and other components that can

The hypoglycemic eﬀects of yam gruel

Figure 7: Eﬀects of yam gruel on the levels of GLP-1 and PYY in
serum. (a) GLP-1 levels of each group. (b) PYY levels of each group.
Values are expressed as mean ± SD, n = 7 or 8. *P < 0.05 and **P <
0.01 vs NC group, #P < 0.05 and ##P < 0.01 vs DM group.

regulate intestinal probiotic bacteria to play a role in
lowering blood glucose [22]. Lyte et al. [23] found that
the number of probiotics signiﬁcantly increased and the
level of FBG decreased after treatment with resistant
starch for 6 weeks in T2DM mice. Moreover, the content
of dietary ﬁber was negatively correlated with blood
glucose [24]. In particular, the increase in water-soluble
dietary ﬁber can be fermented by intestinal probiotic
bacteria to produce SCFAs. The increase in SCFAs can
subsequently reduce the pH value in the intestinal tract,
enhancing the acidic environment of the intestinal tract
and promoting the growth of probiotics so as to achieve
the goal of reducing blood glucose.
GPR43 is an essential member of the orphan receptor
in the G protein-coupled receptor superfamily and is also
the speciﬁc receptor of various SCFAs. Kim [25] proposed
that the content of SCFAs was positively correlated with
the expression of GPR43 receptor and that a high
concentration of SCFAs could upregulate the level of
gene and protein expression of GPR43 receptor. This was
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consistent with the views of Liang et al. [26]. GPR43
receptor has been found to be closely related to the
development of T2DM [27]. Activation of GPR43 receptor
could increase Ca2+ in intestinal L cells, further
promoting the secretion of GLP-1 and PYY so as to lower
the level of FBG. It has been demonstrated that mice with
GPR43 gene knockout presented an obese phenotype,
excessive accumulation of fat, and predisposition to
obstacles of insulin signal transmission, thus inducing
insulin resistance [28]. According to an animal experiment, supplementation with probiotic bacteria upregulated the expression of GPR43 receptor, repaired glucose
intolerance, and reduced the level of blood glucose in
T2DM rats [29]. Furthermore, the mechanism of action
may be related to the improvement of the concentration
of SCFAs. In our study, yam gruel treatment enhanced the
expression of GPR43 receptor in colon tissues, which may
be due to the increased abundance of probiotic bacteria.
The increased probiotic abundance stimulating the
content of SCFAs in turn may have facilitated the
upregulation of GPR43 receptor.
GLP-1 and PYY are gastrointestinal peptide hormones secreted by L cells at the end of the small
intestine and the colon. They play an important role in
regulating appetite, reducing body mass, and maintaining blood glucose stable [30]. Previous studies have
shown that in the pathological state of T2DM, intestinal L
cells display dysfunctions of secretion and GLP-1 and
PYY levels are signiﬁcantly lower than usual [31].
Interestingly, increases in the population of GLP-1 and
PYY can signiﬁcantly ameliorate the insulin resistance
and glucose homeostasis of T2DM [32]. For one, GLP-1
can help to promote the proliferation and regeneration of
β-cells, prevent their apoptosis, and stimulate the
secretion of insulin. In addition, it also inhibits the
secretion of glucagon by α-cells in a glucose-dependent
mode. This not only has an eﬀect on the reduction of
FBG but can also eﬀectively prevent the occurrence of
hypoglycemia [33]. Additionally, GLP-1 is expected to
exert an impact on appetite regulation and food
absorption to control body weight. Compared with
GLP-1, PYY reduced the level of FBG mainly by delaying
the emptying of gastric content, enhancing satiety,
reducing food intake, and controlling body weight to
improve insulin sensitivity [34]. Our data showed that
the content of GLP-1 and PYY in serum was reduced
notably in T2DM rats. Dietary supplementation of yam
gruel, on the other hand, elevated serum GLP-1 and PYY
levels. This was mainly due to the active ingredient of
yam in yam gruel. Resistant starch and dietary ﬁber in
Chinese yam can increase the content of SCFAs [35],
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which may help to upregulate the expression of GPR43
receptor. Psichas et al. [36] conﬁrmed that SCFAs
signiﬁcantly promoted GLP-1 and PYY secretion through
an animal experiment. SCFAs are considered the most
eﬀective ligand for GPR43 receptor. The binding of
GPR43 receptor and SCFAs can likely stimulate intestinal
L cells to secrete GLP-1, PYY, and other gastrointestinal
peptide hormones so as to exert an antidiabetic function [13].
In conclusion, our study indicated that dietary
supplementation with yam gruel could promote the
growth of probiotic bacteria and SCFAs in T2DM rats,
thus upregulating the expression of GPR43 receptor in
colon tissues and increasing serum GLP-1 and PYY
levels. All of these factors may work together to trigger
yam gruel’s antidiabetic eﬀects. These ﬁndings may be
valuable for the prevention and treatment of diabetes
with safer, natural compounds.
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